CSPC is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $17.8B combined in 2025.
| Drug | Brand owner | Copy | US LOE | CSPC's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Dupixent | Sanofi / Regeneron | Biosimilar | 2031 | Clinical trials approved in China | $17.8B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not CSPC's share of it.